Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effects

Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study.

The trial reported that 19% of participants discontinued the treatment, citing adverse effects as the primary reason.

The high discontinuation rate raises concerns about the tolerability of the GLP-1 based injection and may affect its path to regulatory approval.

Analysts will watch how the safety profile influences Boehringer’s obesity pipeline and potential market launch.